Volume 120, Issue 2 pp. 217-222

Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma

Delin Zhu

Delin Zhu

Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals, Southampton, and

Search for more papers by this author
Christian H. Ottensmeier

Christian H. Ottensmeier

Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals, Southampton, and

Search for more papers by this author
Ming-Qing Du

Ming-Qing Du

Department of Histopathology, University College London, London, UK

Search for more papers by this author
Helen McCarthy

Helen McCarthy

Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals, Southampton, and

Search for more papers by this author
Freda K. Stevenson

Freda K. Stevenson

Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals, Southampton, and

Search for more papers by this author
First published: 24 January 2003
Citations: 61
Dr Delin Zhu, Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals, Southampton SO16 6YD, UK. E-mail: [email protected]

Abstract

Summary. Recently, a high incidence of novel N-glycosylation sites introduced by somatic mutation was observed in the immunoglobulin variable region genes of follicular lymphoma. As these are positively selected and are uncommon in normal B cells, they may have a role in tumour growth and behaviour. Sites are not characteristic of chronic lymphocytic leukaemia or myeloma, but are detectable in ∼50% of diffuse large cell lymphomas. Another feature of the variable region genes of certain lymphomas is ongoing somatic mutation. To determine whether glycosylation is associated with this phenomenon, we analysed variable region gene sequences of Burkitt's lymphoma (BL) and mucosa-associated lymphoid tissue (MALT) lymphoma. Novel sites were common in endemic BL (82%) and in 4/5 patients with Iranian BL. However, sporadic BL had a lower incidence (43%). Patients with MALT lymphoma had a low frequency (9%) of novel sites, comparable to normal B cells. These findings distinguish glycosylation sites from ongoing mutation and may reflect different environmental influences on these tumours.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.